[go: up one dir, main page]

PE20110283A1 - Composicion que contiene nifurtimox - Google Patents

Composicion que contiene nifurtimox

Info

Publication number
PE20110283A1
PE20110283A1 PE2010001201A PE2010001201A PE20110283A1 PE 20110283 A1 PE20110283 A1 PE 20110283A1 PE 2010001201 A PE2010001201 A PE 2010001201A PE 2010001201 A PE2010001201 A PE 2010001201A PE 20110283 A1 PE20110283 A1 PE 20110283A1
Authority
PE
Peru
Prior art keywords
composition containing
nifurtimox
composition
containing nifurtimox
cyclooctadepsipeptides
Prior art date
Application number
PE2010001201A
Other languages
English (en)
Inventor
Gisela Greif
Achim Harder
Thomas Bach
Gabriele Petry
Eva-Maria Kruedewagen
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of PE20110283A1 publication Critical patent/PE20110283A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Fodder In General (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Catching Or Destruction (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

SE REFIERE A UNA COMPOSICION VETERINARIA QUE CONTIENE: A) NIFURTIMOX; Y B) OTRO PRINCIPIO ACTIVO SELECCIONADO ENTRE ANTIHELMINTICOS CICLOOCTADEPSIPEPTIDOS COMO EL EMODEPSIDO, ROBENIDINA, PIRIMETAMINA, CLINDAMICINA, SULFADIAZINA, ENTRE OTROS. DICHA COMPOSICION ES DE APLICACION ENTERAL, PARENTERAL O DERMICA SIENDO UTIL EN EL TRATAMIENTO DE ENFERMEDADES CAUSADAS POR GIARDIAS
PE2010001201A 2008-07-02 2009-06-20 Composicion que contiene nifurtimox PE20110283A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102008031284A DE102008031284A1 (de) 2008-07-02 2008-07-02 Neue Bekämpfungsmöglichkeit der Giardiose

Publications (1)

Publication Number Publication Date
PE20110283A1 true PE20110283A1 (es) 2011-05-07

Family

ID=41077987

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2010001201A PE20110283A1 (es) 2008-07-02 2009-06-20 Composicion que contiene nifurtimox

Country Status (29)

Country Link
US (1) US8440612B2 (es)
EP (1) EP2310018B1 (es)
JP (1) JP5627579B2 (es)
KR (1) KR101720805B1 (es)
CN (1) CN102083441B (es)
AR (1) AR072425A1 (es)
AU (1) AU2009266125B2 (es)
BR (1) BRPI0913889B1 (es)
CA (1) CA2729730C (es)
CL (2) CL2010001577A1 (es)
CO (1) CO6321270A2 (es)
CR (1) CR20110022A (es)
DE (1) DE102008031284A1 (es)
DK (1) DK2310018T3 (es)
DO (1) DOP2010000405A (es)
EC (1) ECSP10010720A (es)
ES (1) ES2444581T3 (es)
IL (1) IL209698A (es)
MX (1) MX2010014446A (es)
MY (1) MY157007A (es)
NI (1) NI201100008A (es)
NZ (1) NZ590276A (es)
PE (1) PE20110283A1 (es)
PL (1) PL2310018T3 (es)
RU (1) RU2538713C9 (es)
SV (1) SV2011003785A (es)
UA (1) UA103328C2 (es)
WO (1) WO2010000399A1 (es)
ZA (1) ZA201009225B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012051251A1 (en) * 2010-10-12 2012-04-19 The Usa, As Repr. By The Secrt, Dept. Of Health & Human Serv. Office Of Technology Transfer, Methods of treating giardiasis
BR112017024773A2 (pt) 2015-05-20 2018-11-06 Merial, Inc. compostos depsipeptídeos anti-helmínticos
HK1255391A1 (zh) 2015-12-28 2019-08-16 Boehringer Ingelheim Animal Health USA Inc. 驱虫的缩酚酸肽化合物
WO2018093920A1 (en) 2016-11-16 2018-05-24 Merial, Inc. Anthelmintic depsipeptide compounds
EP3750527A1 (en) * 2019-06-13 2020-12-16 Bayer AG Stable tablet formulation of nifurtimox and process for producing the same
CN114377018B (zh) * 2020-10-21 2024-02-06 中国医学科学院药物研究所 硝呋莫司在制备抗流感病毒药物中的应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1170957B (de) * 1962-11-23 1964-05-27 Bayer Ag Verfahren zur Herstellung von 5-Nitro-furfuryliden-(2)-iminoderivaten
JPH081908B2 (ja) * 1987-07-22 1996-01-10 三菱電機株式会社 超格子半導体素子
NO176766C (no) 1989-02-07 1995-05-24 Meiji Seika Kaisha Fremgangsmåte for fremstilling av en forbindelse med anthelmintaktivitet
DE69331414T2 (de) 1992-03-17 2002-08-08 Fujisawa Pharmaceutical Co., Ltd. Depsipeptide, herstellung und anwendung
DE4317458A1 (de) 1992-06-11 1993-12-16 Bayer Ag Verwendung von cyclischen Depsipeptiden mit 18 Ringatomen zur Bekämpfung von Endoparasiten, neue cyclische Depsipeptide mit 18 Ringatomen und Verfahren zu ihrer Herstellung
EP0685469A4 (en) 1993-02-19 1996-04-03 Meiji Seika Kaisha DERIVATIVE OF PF 1022 USED AS A CYCLIC DEPSIPEPTIDE.
DE4317432A1 (de) * 1993-05-26 1994-12-01 Bayer Ag Octacyclodepsipeptide mit endoparasitizider Wirkung
DE4317457A1 (de) 1993-05-26 1994-12-01 Bayer Ag Octacyclodepsipeptide mit endoparasitizider Wirkung
BR9407711A (pt) * 1993-09-06 1997-02-12 Fujisawa Pharmaceutical Co Composto de ciclopeptídeo processo para preparaçao de um composto de ciclopeptídeo e parasiticida
DE4401389A1 (de) * 1994-01-19 1995-07-20 Bayer Ag Verwendung von cyclischen Depsipeptiden mit 12 Ringatomen zur Bekämpfung von Endoparasiten, neue cyclische Depsipeptide mit 12 Ringatomen und Verfahren zu ihrer Herstellung
DE4406025A1 (de) * 1994-02-24 1995-08-31 Bayer Ag Milchsäure-haltige cyclische Depsipeptide mit 18 Ringatomen als endoparasitizide Mittel und Verfahren zu ihrer Herstellung
DE4437198A1 (de) 1994-10-18 1996-04-25 Bayer Ag Verfahren zur Sulfonylierung, Sulfenylierung und Phosphorylierung von cyclischen Depsipeptiden
PT872481E (pt) 1995-06-30 2009-05-20 Astellas Pharma Inc Derivado de depsipéptido, processo para a sua produção, e novos intermediários do mesmo
ATE299871T1 (de) 1995-09-22 2005-08-15 Meiji Seika Kaisha Neue zyklische depsipeptid pf1022 derivate
DE19545639A1 (de) 1995-12-07 1997-06-12 Bayer Ag Verfahren zur Herstellung von substituierten Arylmilchsäure-haltigen Cyclodepsipeptiden mit 24 Ringatomen
US6503881B2 (en) * 1996-08-21 2003-01-07 Micrologix Biotech Inc. Compositions and methods for treating infections using cationic peptides alone or in combination with antibiotics
US5874630A (en) * 1998-01-06 1999-02-23 Occidental Chemical Corporation Synthesis of mercaptans from alcohols
US6133228A (en) * 1998-05-28 2000-10-17 Firmenich Sa Slow release of fragrant compounds in perfumery using 2-benzoyl benzoates, 2-alkanoyl benzoates or α-keto esters
DE19828047A1 (de) * 1998-06-24 1999-12-30 Bayer Ag Substituierte Cyclooctadepsipeptide
CA2586950A1 (en) * 2004-11-12 2006-05-18 Celgene Corporation Methods and compositions using immunomodulatory compounds for treatment and management of parasitic diseases
DE102005033496A1 (de) 2005-07-19 2007-01-25 Bayer Healthcare Ag Desinfektionsmittel

Also Published As

Publication number Publication date
CA2729730A1 (en) 2010-01-07
IL209698A0 (en) 2011-02-28
CL2010001577A1 (es) 2011-05-06
JP5627579B2 (ja) 2014-11-19
EP2310018A1 (de) 2011-04-20
WO2010000399A1 (de) 2010-01-07
MX2010014446A (es) 2011-02-22
ZA201009225B (en) 2012-03-28
CN102083441A (zh) 2011-06-01
US20110105388A1 (en) 2011-05-05
PL2310018T3 (pl) 2014-05-30
AR072425A1 (es) 2010-08-25
DOP2010000405A (es) 2011-01-15
DE102008031284A1 (de) 2010-01-07
AU2009266125A1 (en) 2010-01-07
HK1158113A1 (en) 2012-07-13
MY157007A (en) 2016-04-15
RU2011103475A (ru) 2012-08-10
CA2729730C (en) 2016-03-22
RU2538713C2 (ru) 2015-01-10
CL2013000709A1 (es) 2013-08-23
RU2538713C9 (ru) 2015-08-20
NZ590276A (en) 2012-12-21
ECSP10010720A (es) 2011-01-31
EP2310018B1 (de) 2013-12-18
CN102083441B (zh) 2013-07-24
NI201100008A (es) 2011-08-10
IL209698A (en) 2016-03-31
BRPI0913889B1 (pt) 2019-02-05
CR20110022A (es) 2011-05-10
KR101720805B1 (ko) 2017-03-28
JP2011526265A (ja) 2011-10-06
ES2444581T3 (es) 2014-02-25
AU2009266125B2 (en) 2015-06-04
US8440612B2 (en) 2013-05-14
CO6321270A2 (es) 2011-09-20
UA103328C2 (uk) 2013-10-10
KR20110031357A (ko) 2011-03-25
SV2011003785A (es) 2011-05-20
BRPI0913889A2 (pt) 2015-10-27
DK2310018T3 (da) 2014-03-24

Similar Documents

Publication Publication Date Title
PE20110283A1 (es) Composicion que contiene nifurtimox
CR10748A (es) Compuesto de indol
CL2011001082A1 (es) Compuestos derivados de amino-tetrahidropiranos sustituidos con heterociclos, composicion farmaceutica; y uso en el tratamiento de una afeccion seleccionada de resistencia a la insulina, hiperglicemia y diabetes de tipo 2.
CO6821938A2 (es) Un compuesto de guanidina o una sal del mismo para el tratamiento de enfermedades relacionadas con vap -1
BRPI1015229A2 (pt) Seringa pré-abastecida ou auto-injetor.
CL2008001612A1 (es) 5-(3-hidroxi-7-sustituido-naftalen-2-il)-1, 1-dioxo-[1,2,5]tiadiazolidin-3-ona; su uso para tratar un trastorno hiperproliferativo; la composicion farmaceutica que los contiene; y sus procesos de preparacion.
MX350541B (es) Materiales y metodos para mejorar la funcion gastrointestinal.
CO6680667A2 (es) Derivados ester de ácido borónico cíclico y sus usos terapéuticos
CL2015001792A1 (es) Una composicion que comprende (i) un complejo de haluro de (aminoacido o trialquil glicina) y zinc y (ii) cisteina, util para la eliminacion de las bacterias, la reduccion de la transpiracion y/o la reduccion del olor corporal, o para el cuidado oral, entre otras.
AR093386A1 (es) Composicion para tratar la diabetes o la diabesidad que comprende un analogo de oxintomodulina y metodo de tratamiento
EA201170876A1 (ru) Применение способной к вспениванию композиции, по существу, не содержащей фармацевтически активные ингредиенты, для лечения кожи человека
CL2008001197A1 (es) Compuestos derivados de amidas sustituidas, moduladoras de la actividad de la enzima 11-beta-hidroxiesteroide deshidrogenasa tipo i; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como sindrome metabolico, resistencia a la insulina, dislipidemia, entre otras.
CR20150174A (es) Composición esterilizada que comprende al menos un ácido hialuronico y ascorbil fosfato de magnesio
PE20121709A1 (es) Una composicion farmaceutica para tratar cancer que comprende tripsinogeno y/o quimotripsinogeno y un agente activo seleccionado a partir de un compuesto de selenio, un compuesto vainilloide y un agente reductor de glicolisis citoplasmica
CL2010001260A1 (es) Composicion farmaceutica que comprende una sal de estroncio y vitamina d y una ciclodextrina, donde la relacion masica entre la cantidad de vitamina d y la cantidad de ciclodextrina esta comprendida entre 1/40 y 1/800, util para tratar o prevenir osteoporosis.
CL2016000950A1 (es) Composición farmacéutica acuosa que comprende insulina glulisina y metionina; kit farmacéutico; uso en el tratamiento de la diabetes tipo 1 ó 2.
CO6410278A2 (es) Disoluciones pediátricas que continen un beta-bloqueante
UY30158A1 (es) Uso de derivados de benzo-heteroaril sulfamida para el tratamiento del dolor
CL2011002182A1 (es) Compuestos heterociclicos que contienen 2 o mas heterociclos con n como heteroatomos del ciclo, agonistas de gpr119 e inhibidores de dpp-iv; composicion farmaceutica; y su uso en el tratamiento de la diabetes tipo ii, obesidad, sindrome metabolico, tolerancia deteriorada a la glucosa e hiperlipidemia, entre otras enfermedades..
PE20130379A1 (es) Metodos para el tratamiento de las ulceras del pie diabetico
EA201390090A1 (ru) Дезинфицирующий и антисептический препарат, имеющий сниженное содержание йода
CL2012003266A1 (es) Polisacarido de semillas de tamarindo para usarse en el tratamiento de infecciones microbianas; composicion farmacéutica y/o dermocosmética antimicrobiana que contiene dicho polisacárido; uso de un polisacárido de semilla de tamarindo ; metodo para tratar y/o prevenir a un paciente que tiene una infeccion microbiana.
PE20121538A1 (es) Combinaciones terapeuticas de teobromina y una antihistamina
PE20110370A1 (es) Nifurtimox para el tratamiento de enfermedades causadas por trichomonadida
BR112014014207A2 (pt) análogos de magnolol solubilizados

Legal Events

Date Code Title Description
FC Refusal